✦ LIBER ✦

P2.204 A randomized, double-blind, placebo-controlled, delayed start study to assess safty, tolerability and efflcacy of green tea polyphenols in Parkinson's disease

✍ Scribed by P. Chan; Z. Qin; Z. Zheng; L. Zhang; X. Fang; F. Sun; Z. Gu; S. Chen; J. Ma; C. Meng; J.W. Langston; C.M. Tanner

Book ID: 117753758
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 65 KB
Volume: 15
Category: Article
ISSN: 1353-8020
DOI: 10.1016/s1353-8020(09)70555-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

✍ C. Warren Olanow; Robert A. Hauser; Joseph Jankovic; William Langston; Anthony L 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 1 views

## Abstract A neuroprotective therapy is the single most important unmet medical need in Parkinson's disease. Several promising agents in the laboratory have been tested in the clinic, but none has been established in clinical trials to have a disease modifying effect despite positive results becau

Mo2083 A Randomized, Double-Blind, Place

Mo2083 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease

✍ Stephan R. Targan; Brian G. Feagan; Severine Vermeire; Remo Panaccione; Gil Y. M 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 89 KB

A prospective randomized double blind pl

A prospective randomized double blind placebo controlled study to assess the efficacy of intravenous loading of azatilloprine in children and adolescents with inflammatory bowel disease

✍ Howard A. Kader; Yves Theoret; Vasundhara Tolia; Chris A. Liacouras; David A. Pi 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 188 KB

A 24-week, randomized, double-blind, pla

A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease

✍ Nakamura, Yu; Imai, Yukimichi; Shigeta, Masahiro; Graf, Ana; Shirahase, Toru; Ki 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Phase II, clinical evaluation of 2% poly

Phase II, clinical evaluation of 2% polyphenone (green tea extract) in a hydrophilic gel to assess improvement in damaged and premature aged facial skin. a placebo-controlled, double-blind study

✍ Tanweer A Syed; Wendy H. Wong; Seyed Ali Ahmad; Raza Aly 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 52 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre